Anagenex is an early-stage drug discovery company using machine learning to inform DNA-encoded library screens and expedite drug development.

Anagenex is building a novel drug discovery platform that utilizes large, iterative DNA-encoded drug libraries and machine learning to enable drug discovery against difficult targets. Their platform allows them to test over 1000x more compounds than conventional drug screening approaches and rapidly assess each by computationally determining critical relationships between chemical structure and activity—all at significantly reduced time and cost.  Anagenex is exploring several high-value targets with validated disease relevance or a strong biology thesis across oncology, inflammatory disorders, musculoskeletal disorders and cardiovascular medicine to maximize the value of their platform.

No items found.